Friday, 16 October 2026European Markets

QUESTERRE ENERGY Stock Is 14% Up So Far Today

Loading stream...

(VIANEWS) - Shares of QUESTERRE ENERGY (Oslo Børs Benchmark Index_GI: QEC.OL) jumped by a staggering 14.17% to kr2.06 at 11:40 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is rising 1.16% to kr1,207.38, after five successive sessions in a row of gains. This seems, up until now, an all-around positive trend trading session today.

QUESTERRE ENERGY's last close was kr1.80, 28.85% below its 52-week high of kr2.53.

About QUESTERRE ENERGY

Questerre Energy Corporation acquires, explores, and develops non-conventional oil and gas projects in Canada. It produces tight oil, oil shale, shale oil, and shale gas. The company primarily holds 40,960 acres located in Kakwa, west central Alberta, including a 25% working interest in 10,080 acres in Kakwa Central; 50% working interest in 4,480 acres in Kakwa North; 50% interest in 22,400 acres in Kakwa West; and 50% interest in 3,840 acres in Kakwa South. It also holds 100% working interest in 11,035 acres located in Antler, Saskatchewan; and oil shale assets in Jordan. The company was formerly known as Westpro Equipment Ltd. and changed its name to Questerre Energy Corporation in December 2000. The company was incorporated in 1971 and is headquartered in Calgary, Canada.

Earnings Per Share

As for profitability, QUESTERRE ENERGY has a trailing twelve months EPS of kr-1.89.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.96%.

Volume

Today's last reported volume for QUESTERRE ENERGY is 3690531 which is 81.09% above its average volume of 2037950.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45.5%, now sitting on 46.92M for the twelve trailing months.

More news about QUESTERRE ENERGY (QEC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com